Reuters logo
BRIEF-TG therapeutics announces completion of enrollment and B-cell depletion data from part 1 of ongoing phase 2 multiple sclerosis study
January 11, 2017 / 12:39 PM / in a year

BRIEF-TG therapeutics announces completion of enrollment and B-cell depletion data from part 1 of ongoing phase 2 multiple sclerosis study

Jan 11 (Reuters) - TG Therapeutics Inc

* TG therapeutics announces completion of enrollment and B-cell depletion data from part 1 of ongoing phase 2 multiple sclerosis study

* TG Therapeutics Inc says phase 3 MS program planned to initiate in 1H 2017

* TG Therapeutics Inc says TG-1101 was well tolerated with no grade 3/4 adverse events reported

* TG Therapeutics Inc says early data demonstrates rapid and profound B-cell reductions in ms patients treated with TG-1101 with median B-cell reduction of 99%

* As part 2 of trial, company has added expansion cohorts and will explore accelerated dosing of initial 150mg dose Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below